16574
document
Correlates of cognitive deficits in first episode schizophrenia . OBJECTIVE The presence of cognitive dysfunction in schizophrenia has been well documented , but questions remain about whether there are relationships between this dysfunction and clinical symptomatology . If present , such relationships should be most clearly observable in patients with first episode schizophrenia ; that is , before the effects of chronic illness , institutionalization , or treatment might confound them . METHOD 307 schizophrenia subjects in their first episode of illness were recruited to participate in a clinical trial comparing the long-term efficacy of haloperidol and risperidone . The psychopathology , cognitive functioning , early treatment history , and duration of untreated psychosis of these subjects were assessed prior to their assignment to randomized , double-blind treatment . Approximately two-thirds of the subjects were receiving antipsychotic treatment at the time of assessment ; however , the duration of treatment was limited to 12 weeks or less . RESULTS The severity of negative symptoms at the time of assessment was associated with deficits in memory , verbal fluency , psychomotor speed and executive function . Positive symptoms were not associated with cognitive deficits . Also , the duration of untreated illness ( DUI ) prior to assessment was not significantly associated with cognitive impairment . CONCLUSIONS The results of this study of first episode schizophrenia patients suggest that a relationship exists between negative symptoms and cognitive dysfunction . However , that relationship accounts for only a minor portion of the variance ( i.e. , 10-15 % ) in the severity of cognitive dysfunction after controlling for a number of potentially confounding factors . This finding provides support for the theory that the neurobiological processes that give rise to symptomatology and cognitive dysfunction in schizophrenia are partially overlapping .
16575
Intervention_Pharmacological
haloperidol and risperidone
16576
Intervention_Pharmacological
antipsychotic treatment
16577
Outcome_Physical
cognitive deficits
16578
Outcome_Physical
cognitive dysfunction
16579
Outcome_Physical
dysfunction
16580
Outcome_Physical
clinical symptomatology .
16581
Outcome_Physical
severity of negative symptoms
16582
Outcome_Mental
deficits in memory
16583
Outcome_Mental
verbal fluency
16584
Outcome_Mental
psychomotor speed
16585
Outcome_Physical
executive function
16586
Outcome_Physical
Positive symptoms
16587
Outcome_Physical
cognitive deficits
16588
Outcome_Physical
duration of untreated illness ( DUI )
16589
Outcome_Physical
cognitive impairment
16590
Outcome_Physical
negative symptoms
16591
Outcome_Mental
cognitive dysfunction
16592
Outcome_Mental
severity of cognitive dysfunction
16593
Outcome_Other
symptomatology
16594
Outcome_Physical
cognitive dysfunction
16595
Participant_Condition
first episode schizophrenia
16596
Participant_Condition
schizophrenia
16597
Participant_Condition
first episode schizophrenia
16598
Participant_Condition
chronic illness
16599
Participant_Sample-size
307
16600
Participant_Condition
schizophrenia
16601
Participant_Condition
first episode of illness
16602
Participant_Sample-size
two-thirds
16603
Participant_Condition
first episode schizophrenia
16604
Participant_Condition
schizophrenia